NCT05990738 - DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

July 30, 2027

Conditions

Small Cell Lung Carcinoma (SCLC)

Interventions

DRUG

BI 764532

DRUG

Topotecan

DRUG

Single agent chemotherapy

single agent chemotherapy

Trial Locations (16)

20007

NOT_YET_RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

23298

NOT_YET_RECRUITING

Virginia Commonwealth University, Richmond

27834

NOT_YET_RECRUITING

East Carolina University, Greenville

32224

RECRUITING

Mayo Clinic - Florida, Jacksonville

33136

RECRUITING

University of Miami, Miami

55131

RECRUITING

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

66205

NOT_YET_RECRUITING

University of Kansas Cancer Center, Westwood

67091

RECRUITING

HOP Civil, Strasbourg

69126

RECRUITING

Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg

75005

RECRUITING

INS Curie, Paris

91054

RECRUITING

Universitätsklinikum Erlangen, Erlangen

94805

RECRUITING

INS Gustave Roussy, Villejuif

97078

RECRUITING

Universitätsklinikum Würzburg AÖR, Würzburg

01307

RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

93-338

RECRUITING

Polish Mother's Memorial Hospital - Research Institute, Lodz

LE1 5WW

RECRUITING

Leicester Royal Infirmary, Leicester